Literature DB >> 25557842

Attenuation of morphine-induced dependence and tolerance by ceftriaxone and amitriptyline in mice.

Bohlul Habibi-Asl1, Haleh Vaez1, Moslem Najafi1, Ali Bidaghi2, Saeed Ghanbarzadeh3.   

Abstract

INTRODUCTION: Tolerance to and dependence on the analgesic effect of opioids is a pharmacological phenomenon that occurs after their prolonged administration.
OBJECTIVE: The aim of this study was to evaluate the protective effects of ceftriaxone and amitriptyline on the development of morphine-induced tolerance and dependence.
METHODS: In this study, 18 groups (9 groups each for tolerance and dependency tests) of mice (n = 8) received saline [10 mL/kg, intraperitoneally (i.p.)], morphine (50 mg/kg, i.p.), ceftriaxone (50 mg/kg, i.p., 100 mg/kg, i.p., and 200 mg/kg, i.p.), amitriptyline (5 mg/kg, i.p., 10 mg/kg, i.p., and 15 mg/kg, i.p.), or a combination of ceftriaxone (50 mg/kg, i.p.) and amitriptyline (5 mg/kg, i.p.) once per day for 4 days for investigation and comparison of the effects of ceftriaxone and amitriptyline on the prevention of dependency and tolerance to morphine. Tolerance was assessed with administration of morphine (9 mg/kg, i.p.) and using the hot plate test on the 5(th) day. In dependency tests, withdrawal symptoms were assessed on the 4(th) day for each animal 30 minutes after the administration of naloxone (4 mg/kg, i.p.; 2 hours after the last dose of morphine).
RESULTS: It was found that treatment with ceftriaxone or amitriptyline attenuated the development of tolerance to the antinociceptive effect of morphine and also reduced naloxone-precipitated withdrawal jumping and standing on feet. Furthermore, coadministration of ceftriaxone and amitriptyline at low doses (50 mg/kg, i.p. and 5 mg/kg, i.p., respectively) prior to morphine injection also decreased both morphine-induced tolerance and dependence.
CONCLUSION: Results indicate that the treatment with ceftriaxone and amitriptyline, alone or in combination, could attenuate the development of morphine-induced tolerance and dependence.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  amitriptyline; ceftriaxone; dependency; morphine; tolerance; β-lactam antibiotic

Mesh:

Substances:

Year:  2014        PMID: 25557842     DOI: 10.1016/j.aat.2014.11.001

Source DB:  PubMed          Journal:  Acta Anaesthesiol Taiwan


  7 in total

1.  Nephroprotective efficacy of ceftriaxone against cisplatin-induced subchronic renal fibrosis in rats.

Authors:  Mohamed M Abdel-Daim; Yasser S El-Sayed; Mabrouk Abd Eldaim; Abdelazim Ibrahim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-14       Impact factor: 3.000

2.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 3.  Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation.

Authors:  Osama A Abulseoud; Fawaz Alasmari; Abdelaziz M Hussein; Youssef Sari
Journal:  Front Neurosci       Date:  2022-07-05       Impact factor: 5.152

4.  Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence.

Authors:  Xiaoyan Lin; Amey S Dhopeshwarkar; Megan Huibregtse; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2017-11-30       Impact factor: 4.436

5.  Two New βN-Alkanoyl-5-Hydroxytryptamides with Relevant Antinociceptive Activity.

Authors:  Jorge Luis Amorim; Fernanda Alves Lima; Ana Laura Macedo Brand; Silvio Cunha; Claudia Moraes Rezende; Patricia Dias Fernandes
Journal:  Biomedicines       Date:  2021-04-22

Review 6.  Targeting Cytokines for Morphine Tolerance: A Narrative Review.

Authors:  Dai-Qiang Liu; Ya-Qun Zhou; Feng Gao
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

7.  Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction.

Authors:  Pss Rao; Murali M Yallapu; Youssef Sari; Paul B Fisher; Santosh Kumar
Journal:  J Pers Nanomed       Date:  2015-07-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.